Blogs

Blog

As Drug Delivery Evolves, So Must Patient Training

Higher-dose and larger-volume subcutaneous therapies are creating new possibilities for drug delivery, including programs exploring the transition from intravenous (IV) to subcutaneous (SC) administration. A 2024 systematic review identified 182 clinical-stage or approved large-volume SC biopharmaceuticals, defined by the authors as doses greater than 2 mL, spanning oncology and a range of chronic disease areas.

Learn more

Blog

Beyond the Device: Key Takeaways from PDA PFS 2026

The 2026 PDA Universe of Pre-Filled Syringes and Injection Devices Conference brought the drug delivery community together in Palm Springs around the theme, “Where Molecules Meet Devices: Advancing Patient-Centric Solutions.” Across the program, the intersection of drug delivery, device development, combination products, technology and user experience was front and center.

Learn more

Blog

Device Differences Matter: Why Addressing Negative Transfer Is Critical to Biosimilar Success

As biosimilar and interchangeable biologic therapies continue to expand patient access to treatment, the industry has an opportunity to focus on more than affordability and availability. The patient experience must remain a priority, particularly as new delivery devices enter the market.

Learn more

Blog

What an Entrepreneurial Mindset Means in Pharma and Medical Device Development 

Innovation is a constant in pharma and medical device development. But what separates true industry leaders is not just innovation—it’s an entrepreneurial mindset.

Learn more

Blog

How Pharma Teams Should Approach Autoinjector Device Selection and Design Strategy

Learn how pharma teams should approach autoinjector device selection and autoinjector design strategy using patient-first insights, human factors, and real-world use to reduce risk and improve adherence.

Learn more

Blog

From Innovation to Adoption: Why New GLP-1 Delivery Routes Require Human Factors and Training from Day One 

GLP-1 therapies continue to transform the treatment landscape for obesity and type 2 diabetes. As innovation accelerates, so too does the evolution of how these therapies are delivered.

Learn more